BUZZ-Arcellx climbs on positive trial data for blood cancer cell therapy

Reuters2024-12-09

** Shares of cell therapy developer Arcellx rise 8% to $91.35 premarket

** Co says its cell therapy anito-cel showed 97% overall response rate in a mid-stage trial testing patients with multiple myeloma, a type of blood cancer

** Overall response rate is the proportion of patients who have a partial or complete response to the therapy

** If approved, anito-cel, developed in partnership with Gilead , will compete with Johnson & Johnson's cell therapy Carvykti

** Brokerage TD Cowen says anito-cel's efficacy remains at least as good as Carvykti, but with superior safety

** ACLX's therapy showed no delayed damage to the nervous system, but three deaths occurred due to adverse events during the trial

** Up to last close, stock up 52.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment